Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer
In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer. Dr Abramson says that they are looking at new mutations within the subgroups, specificallyPI3 kinase mutations, as targets for estrogen receptor positive breast cancer. For HER-2 positive breast cancer there are many new therapies such as, ado-trastuzumab emtansine, pertuzumab, trastuzumab and more. "That's where I really think breast cancer is headed, said Dr Abramson. "We are figuring out how we can target specific subtypes in a better way."
This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
A new study published by the IMS Institute for Healthcare Informatics finds that reimbursement approaches based on cost-per-quality-adjusted-life-year measures rather than drug effectiveness may limit access to innovative cancer treatments.
Two studies, published last week in Journal of Clinical Oncology, report improved survival as well as reduced caregiver burden following early initiation of palliative care in advanced cancer patients.
Studies presented at the annual meting of the Society of Gynecologic Oncology, in Chicago, evaluated the efficacy of an experimental vaccine and an angiogenesis inhibitor in preventing the recurrence of ovarian cancer.
The Global Cancer Project Map is an interactive online database that allows users to search for cancer experts and research projects by country and by cancer type, and then to initiate contact with project principal investigators and program directors.
The study, published in The Journal of Community and Supportive Oncology, discovered cancer survivors perceive gaps in their care with respect to reviewing information, asking questions, obtaining answers, and making decisions.
Currently, Keytruda is approved for patients with advanced melanoma previously treated with Yervoy and, in some patients, another type of drug as well. That second- and third-line status limits the number of patients eligible for the drug.